Unlock instant, AI-driven research and patent intelligence for your innovation.

Humanised antigen binding proteins to myostatin6

A myostatin and binding protein technology, applied in the direction of anti-growth factor immunoglobulin, anti-animal/human immunoglobulin, immunoglobulin, etc., can solve the problems that cannot meet the needs of wider interests and reduce treatment

Inactive Publication Date: 2013-05-08
GLAXO GRP LTD
View PDF54 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Because of these limitations, the need for broader benefits has largely fallen short of the need for treatments for conditions associated with a reduction in any one or a combination of muscle mass, muscle strength, and muscle function

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Humanised antigen binding proteins to myostatin6
  • Humanised antigen binding proteins to myostatin6
  • Humanised antigen binding proteins to myostatin6

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 12

[0560] Example 12: In vivo efficacy of H2L2 variants

[0561] Comparison of the effect of H2L2 anti-myostatin variants with fully functionalized WT Fc domains or with Fc deactivating mutations on muscle growth in male SCID mice aged 7 to 8 weeks using doses of 3, 10, and 30 mg / kg influences. The mouse parent molecule 10B3 was used as a positive control, and was also administered at 3, 10, and 30 mg / kg, and an irrelevant mouse IgG2a isotype control was administered at 30 mg / kg. There are 10 animals in each dose group. The molecules were administered by intraperitoneal injection on days 0, 3, 7, 14 and 21. On the 28th day of the study, the animals were sacrificed, dissected, and the weights of the following muscles were determined: tibialis anterior (TA), quadriceps, extensor digitorum longus (EDL), and gastrocnemius ( Figure 29 ).

[0562] It should be noted that the 10B3 positive control group showed a greater than 10% increase in muscle mass relative to the control animals, w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
affinityaaaaaaaaaa
affinityaaaaaaaaaa
Login to View More

Abstract

The present invention relates to humanised antigen binding proteins, such as antibodies, which bind to myostatin, polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present invention also concerns the use of such humanised antigen binding proteins in the treatment or prophylaxis of diseases associated with any one or a combination of decreased muscle mass, muscle strength and muscle function.

Description

Invention field [0001] The present invention relates to a humanized antigen-binding protein such as an antibody, a polynucleotide encoding the antigen-binding protein, a pharmaceutical composition containing the antigen-binding protein, and a preparation method that bind to myosatin. The present invention also relates to the use of the humanized antigen binding protein to treat or prevent diseases related to any one or a combination of reduced muscle mass, muscle strength and muscle function. Background of the invention [0002] Myostatin, also known as growth and differentiation factor (GDF-8), is a member of the transforming growth factor-β (TGF-β) superfamily and a negative regulator of muscle mass. Myostatin is highly conserved during evolution, and human, chicken, mouse and rat sequences are 100% identical in the mature C-terminal domain. Myostatin is synthesized as a precursor protein that contains a signal sequence, a propeptide domain and a C-terminal domain. The circul...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/22A61K39/395A61P21/06
CPCC07K2317/34C07K2317/567C07K2317/565C07K2317/92C07K16/22C07K2317/71C07K2317/76C07K2317/24A61P1/16A61P11/08A61P13/12A61P17/02A61P19/02A61P19/10A61P21/00A61P21/02A61P21/06A61P25/00A61P25/16A61P3/04A61P31/18A61P35/00A61P9/00A61P9/04A61P3/10
Inventor C·阿什曼S·阿什曼P·A·哈姆布林A·P·路易斯M·A·奥雷基亚
Owner GLAXO GRP LTD